Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Net Income: 2019-2025

Historic Net Income for Kymera Therapeutics (KYMR) over the last 6 years, with Sep 2025 value amounting to -$92.6 million.

  • Kymera Therapeutics' Net Income fell 28.31% to -$92.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$332.6 million, marking a year-over-year decrease of 65.94%. This contributed to the annual value of -$261.9 million for FY2024, which is 58.02% down from last year.
  • As of Q3 2025, Kymera Therapeutics' Net Income stood at -$92.6 million, which was down 9.39% from -$84.7 million recorded in Q2 2025.
  • Kymera Therapeutics' Net Income's 5-year high stood at -$13.2 million during Q1 2021, with a 5-year trough of -$92.6 million in Q3 2025.
  • Over the past 3 years, Kymera Therapeutics' median Net Income value was -$57.9 million (recorded in 2024), while the average stood at -$61.8 million.
  • Its Net Income has fluctuated over the past 5 years, first spiked by 49.95% in 2023, then crashed by 317.34% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Net Income (Quarterly) stood at -$34.0 million in 2021, then decreased by 13.64% to -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then plummeted by 317.34% to -$80.8 million in 2024, then dropped by 28.31% to -$92.6 million in 2025.
  • Its last three reported values are -$92.6 million in Q3 2025, -$84.7 million for Q2 2025, and -$74.5 million during Q1 2025.